To assess the effects of lactate/TPX2 lactylation/AURKA axis inhibition as an intervention for HCC progression in vivo, we employed xenograft model mice generated by subcutaneous inoculation with endogenous TPX2 knockdown HepG2 cells re-expressing TPX2WT or TPX2K249R. The gene discussed is AURKA; the disease is hepatocellular carcinoma.